Disclosure of elevated amyloid status is not associated with long-term suicidality in a preclinical AD trial.

ABSTRACT:

Introduction

The long-term implications of disclosing Alzheimer's disease (AD) biomarker information to cognitively unimpaired individuals are unknown.

Methods

We compared participants who disclosed their elevated amyloid imaging result in a preclinical AD trial to those who disclosed a not elevated result and enrolled in an observational cohort that underwent parallel assessments. Our primary outcome was a score > 0 on the Columbia Suicidality Severity Rating Scale (CSSRS) at any visit; we also considered suicidal behaviors (CSSRS > 5).

Results

Among 1707 total participants (68% elevated amyloid, mean [standard deviation] age 71.5 [4.7], 60% female, 90% non-Hispanic White), followed for a mean 218 (74.1) weeks, there were no suicides and few indications of suicidal t

SUBMITTER: Grill JD 

PROVIDER: S-EPMC11847990 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature